Aktive Positionen von David Urech
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
Numab Therapeutics AG
 Numab Therapeutics AG Miscellaneous Commercial ServicesCommercial Services Numab Therapeutics AG is a biopharmaceutical company, which engages in the development of cancer immunotherapy. Its focuses on creating multi-specific antibodies that enable the pursuit of novel therapeutic strategies. The company was founded by Oliver Middendorp, David Urech, and Peter Lichtlen in 2011 and is headquartered in Wadenswil, Switzerland. | Direktor/Vorstandsmitglied | 01.01.2011 | - |
| Vorstandsvorsitzender | 01.01.2011 | - | |
| Gründer | 01.01.2011 | - | |
| Technik-/Wissenschafts-/F&E-Leiter | 01.01.2011 | - |
Karriereverlauf von David Urech
Ehemalige bekannte Positionen von David Urech
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
ESBATech, a Novartis Co. GmbH
 ESBATech, a Novartis Co. GmbH Miscellaneous Commercial ServicesCommercial Services ESBATech AG develops antibody fragment therapeutics. The firm's antibody fragment is derived from human antibody fragment scaffolds. It develops Immuna, an antigen-independent platform to screen, select, and optimize highly-stable and soluble, single-chain antibody fragments. The company was founded by Dominik Escher in September 1998 and is headquartered Schlieren, Switzerland. | Technik-/Wissenschafts-/F&E-Leiter | - | - |
Ausbildung von David Urech
| University of Zurich | Undergraduate Degree |
| University of Basel | Doctorate Degree |
Statistik
International
| Schweiz | 5 |
Operativ
| Chief Tech/Sci/R&D Officer | 2 |
| Undergraduate Degree | 1 |
| Doctorate Degree | 1 |
Sektoral
| Commercial Services | 3 |
| Consumer Services | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Private Unternehmen | 2 |
|---|---|
ESBATech, a Novartis Co. GmbH
ESBATech, a Novartis Co. GmbH Miscellaneous Commercial ServicesCommercial Services ESBATech AG develops antibody fragment therapeutics. The firm's antibody fragment is derived from human antibody fragment scaffolds. It develops Immuna, an antigen-independent platform to screen, select, and optimize highly-stable and soluble, single-chain antibody fragments. The company was founded by Dominik Escher in September 1998 and is headquartered Schlieren, Switzerland. | Commercial Services |
Numab Therapeutics AG
Numab Therapeutics AG Miscellaneous Commercial ServicesCommercial Services Numab Therapeutics AG is a biopharmaceutical company, which engages in the development of cancer immunotherapy. Its focuses on creating multi-specific antibodies that enable the pursuit of novel therapeutic strategies. The company was founded by Oliver Middendorp, David Urech, and Peter Lichtlen in 2011 and is headquartered in Wadenswil, Switzerland. | Commercial Services |
- Börse
- Insiders
- David Urech
- Erfahrung
